Inbec Tablet Abacavir Dolutegravir Lamivudine

Product Description

Inbec (manufactured by Emcure Pharmaceuticals) provides a complete, co-formulated triple-drug regimen in a single solid-dose oral tablet. Designed to streamline chronic antiretroviral therapy (cART), it reduces pill burden and simplifies adherence schedules by eliminating the need for co-administered companion antiretrovirals. Integrating dolutegravir with a dual-NRTI backbone of abacavir and lamivudine, Inbec targets two distinct phases of the retroviral life cycle, promoting rapid reduction of viral load to undetectable levels while preserving $\text{CD4}^+$ T-cell populations.

Active Pharmaceutical Constituents & Formulation

• Abacavir Sulfate: 600 mg (equivalent to 702 mg abacavir sulfate) — A carbocyclic synthetic purine nucleoside analogue.

• Dolutegravir Sodium: 50 mg (equivalent to 52.6 mg dolutegravir sodium) — A second-generation integrase strand transfer inhibitor (INSTI).

• Lamivudine (3TC): 300 mg — A synthetic cytosine nucleoside analogue.

• Dosage Form: Film-coated, biconvex, capsule-shaped oral tablets manufactured under rigorous current Good Manufacturing Practices (cGMP) for bioequivalence to reference innovator formulations.

Pharmacodynamics & Triple-Target Mechanism of Action

• Integration Blockade (Dolutegravir): Selectively inhibits retroviral integrase by chelating two essential divalent magnesium ions ($\text{Mg}^{2+}$) positioned within the catalytic triad (DDE motif) of the enzyme’s active core. This halts the essential strand-transfer step, preventing the covalent insertion of linearized viral pre-integration cDNA into host chromosomal DNA. The slow dissociation off-rate of dolutegravir provides a high genetic barrier against viral mutational resistance.

• Dual Reverse Transcriptase Inhibition & Chain Termination (Abacavir & Lamivudine):

  • Intracellular Phosphorylation: Following passive cellular uptake, abacavir undergoes multi-step enzymatic biotransformation to its active metabolite, carbovir 5′-triphosphate ($\text{CBV-TP}$). Concurrently, lamivudine is phosphorylated by intracellular deoxycytidine kinases to lamivudine 5′-triphosphate ($\text{3TC-TP}$).

  • Competitive Enzyme Inhibition: Both triphosphates structurally mimic natural endogenous nucleotides (deoxyguanosine triphosphate and deoxycytidine triphosphate, respectively), competitively inhibiting HIV-1 reverse transcriptase.

  • Premature Chain Termination: Because both molecules lack the essential 3′-hydroxyl ($3’\text{-OH}$) group required for phosphodiester bond propagation, their incorporation into nascent viral cDNA causes immediate, irreversible termination of viral DNA synthesis.

Pharmacokinetics & Biotransformation

• Absorption & Food Effect: Rapidly and well-absorbed following oral ingestion. Peak plasma concentrations ($C_{\max}$) are reached within 1.5 to 2.5 hours for abacavir, 2 to 3 hours for dolutegravir, and 1 to 1.5 hours for lamivudine. Inbec can be taken with or without food, as systemic exposure ($\text{AUC}$) is not clinically altered by meals.

• Metabolism & Elimination:

  • Dolutegravir: Cleared hepatically via UDP-glucuronosyltransferase 1A1 ($\text{UGT1A1}$) with minor cytochrome P450 3A4 ($\text{CYP3A4}$) clearance. Displays an elimination half-life of ~14 hours.

  • Abacavir: Extensively metabolized via alcohol dehydrogenase ($\text{ADH}$) and $\text{UGT}$ glucuronidation, avoiding primary cytochrome P450 pathways. Plasma half-life is 1.5 to 2.0 hours, but intracellular $\text{CBV-TP}$ exhibits an extended half-life exceeding 20 hours.

  • Lamivudine: Excreted predominantly unchanged into urine via active organic cationic secretion and glomerular filtration, with a plasma half-life of 5 to 7 hours and an intracellular $\text{3TC-TP}$ half-life of 16 to 19 hours.

Critical Pharmacogenomic Warning: HLA-B*5701 Allele & Hypersensitivity

• Mandatory Screening Requirement: Prior to initiating Inbec therapy, all prospective patients must undergo genetic screening for the human leukocyte antigen allele $\text{HLA-B*5701}$.

• Abacavir Hypersensitivity Reaction (AHR): The carriage of $\text{HLA-B*5701}$ carries a severe risk of triggering an immune-mediated hypersensitivity cascade. Abacavir binds directly within the antigen-presenting groove of the $\text{HLA-B*5701}$ molecule, inducing massive self-reactive $\text{CD8}^+$ T-cell activation. Symptoms typically emerge within the first six weeks of therapy and involve at least two of the following:

  • High fever, constitutional malaise, and fatigue.

  • Maculopapular, confluent, or generalized cutaneous rash.

  • Severe nausea, persistent vomiting, diarrhea, or abdominal pain.

  • Dyspnea, cough, or pharyngitis.

• Permanent Discontinuation: If AHR is suspected, Inbec must be discontinued immediately and permanently. Rechallenging a patient with any abacavir-containing formulation is strictly contraindicated, as it can provoke immediate hemodynamic collapse, multi-organ failure, and death within hours.

Clinical Indications & Prescribing Restrictions

• Indications: Indicated as a complete standalone regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg who are confirmed $\text{HLA-B*5701}$-negative and have no documented phenotypic or genotypic resistance to the INSTI or NRTI classes.

• Renal Function Threshold: Because Inbec is a fixed-dose combination that cannot be individually adjusted, it is not recommended for patients with moderate-to-severe renal impairment (creatinine clearance $\text{CrCl} < 50\text{ mL/min}$), as lamivudine requires dose interval titration below this clearance rate.

Key Drug-Drug Interactions & Safety Warnings

• Polyvalent Metal Cation Chelation: Dolutegravir binds readily to polyvalent metal cations ($\text{Mg}^{2+}, \text{Al}^{3+}, \text{Ca}^{2+}, \text{Fe}^{2+}$). Inbec must be administered at least 2 hours before or 6 hours after taking cation-containing antacids, laxatives, sucralfate, or oral mineral/iron supplements.

• Enzyme Inducers (e.g., Rifampicin): Co-administration with potent metabolic inducers markedly accelerates dolutegravir clearance. Concomitant use with rifampicin requires supplemental single-entity dolutegravir (50 mg taken 12 hours apart from the FDC tablet), which must be coordinated under specialized clinical supervision.

• Metformin Interactions: Dolutegravir inhibits renal transporters $\text{OCT2}$ and $\text{MATE1}$, elevating circulating metformin plasma concentrations. Close blood glucose monitoring and potential metformin dosage reductions are recommended.

• Exacerbation of Hepatitis B (HBV): Lamivudine possesses antiviral activity against HBV. Discontinuation of Inbec in individuals co-infected with HIV-1 and HBV can precipitate acute, severe hepatic flares. Periodic liver function monitoring is required if the drug is stopped.

• Lactic Acidosis & Severe Hepatomegaly with Steatosis: Class-wide warning for nucleoside analogues associated with mitochondrial polymerase-$\gamma$ toxicity, manifesting as metabolic lactic acidosis, tachypnea, and hepatic steatosis.